Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast

Arcutis Biotherapeutics Inc ARQT has obtained a $225 million term loan facility from SLR Capital Partners (SLR). 

  • This additional capital further strengthens Arcutis' balance sheet before a potential 2022 FDA approval & launch of topical roflumilast cream in plaque psoriasis and three 2022 pivotal data readouts in skin disorder trials. 
  • Related: Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review.
  • This non-dilutive financing commitment extends the Company's cash runway into 2024.
  • Under the terms of this loan facility, $75 million was drawn at closing, and an additional $125 million becomes available upon FDA approval of roflumilast cream for plaque psoriasis. 
  • An additional $25 million is also available if certain revenue milestones are achieved. The loan facility maturity date is January 2027.
  • Price Action: ARQT shares traded 1.29% higher at $18.78 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingSmall CapGeneralBriefsPsoriasis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!